Signatera by Natera vs Oncotype DX

Side-by-side comparison of cancer screening tests.

← Back to Cancer Screening

Signatera by Natera

CLIA LDT (CDx approved only for bladder cancer)
Variable

Patient-specific

Oncotype DX

Guideline recommended
Variable

Breast recurrence risk

Test Performance

FeatureSignatera by NateraOncotype DX
PriceVariableVariable
Cancers DetectedPatient-specificBreast recurrence risk
SensitivityVaries by cancerN/A
SpecificityPPV >98%N/A
Sample TypeBlood drawTumor tissue
FDA StatusCLIA LDT (CDx approved only for bladder cancer)Guideline recommended

Get monthly price updates &deals

We track pricing changes across 50+ health testing providers so you don't have to.

Free, once a month. No spam.